Cold Spring Harbor team finds off-target activity can drive antitumor effects

A discovery that 10 drug candidates don't act through their reported target to kill cancer cells suggests companies revise how they validate targets.

Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting unintended targets.

The study also revealed a new target that could be inhibited to treat cancer.

Researchers routinely

Read the full 467 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers